Clinical implications of PD ‐ L1 expression in oncogene‐driven NSCLC : Differential responses to targeted agents and immune checkpoint inhibitors
International Journal of Cancer · 2026
DOI: 10.1002/ijc.70413 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Xiaoxiao Fan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, B7-H1 Antigen, Lung Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Shandong Province, Wu Jieping Medical Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
PD‐L1 is a reliable biomarker for predicting immunotherapy efficacy in NSCLC patients without driver gene mutations. However, its significance in patients with driver gene‐positive tumors remains unclear. This study analyzed 273 patients with stage IV non‐small cell lung cancer harboring driver gene mutations. All patients had PD‐L1 expression levels ≥10%. The effect of PD‐L1 expression on progression‐free survival (PFS) and overall survival (OS) was assessed. Among the 273 patients with driver gene‐positive NSCLC, 127 had a PD‐L1 tumor proportion score (TPS) of 10–49%, and 146 had TPS ≥50%. Patients in the TPS 10%–49% group had significantly better median PFS and OS compared to those in the TPS ≥50% group ( p = 0.0008 and p = 0.0009, respectively). In the realm of targeted therapy, patients who received first‐line tyrosine kinase inhibitors (TKIs) showed superior outcomes in the TPS 10–49% group compared to the TPS ≥50% group in terms of both median PFS (30.8 months vs. 13.9 months, p = .0001) and OS (44.8 months vs. 26.3 months, p = .0006). Regarding immunotherapy, PD‐L1 expression level was not significantly associated with treatment efficacy. However, in patients with KRAS mutations, those who received first‐line immunotherapy exhibited better median PFS and OS ( p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
- Department of Medical Oncology, Huantai County People's Hospital, Zibo, Shandong, China.
- Family & Women-Children Health & Family Planning Division, Health and Wellness Service Center (Center for Disease Control and Prevention) of Binzhou Economic and Technological Development Zone, Binzhou, Shandong, China.
- School of Public Health, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China.
ORCID-Profile: Xiao Han
Förderung
- Natural Science Foundation of Shandong Province
- Wu Jieping Medical Foundation
- National Natural Science Foundation of China
- CSCO-Nav HER2-related Solid Tumors Research Foundation
Zitieren
APA
Fan, X., Wei, C., Rong, M., Wang, S., Wang, J., Wang, X., Han, X., & Meng, X. (2026). Clinical implications of PD ‐ L1 expression in oncogene‐driven NSCLC : Differential responses to targeted agents and immune checkpoint inhibitors. International Journal of Cancer. https://doi.org/10.1002/ijc.70413
Vancouver
Fan X, Wei C, Rong M, Wang S, Wang J, Wang X, et al. Clinical implications of PD ‐ L1 expression in oncogene‐driven NSCLC : Differential responses to targeted agents and immune checkpoint inhibitors. International Journal of Cancer. 2026. doi:10.1002/ijc.70413
BibTeX
@article{Fan2026,
author = {Fan, Xiaoxiao and Wei, Chenxi and Rong, Minjun and Wang, Shengnan and Wang, Jiaying and Wang, Xiaohan and Han, Xiao and Meng, Xue},
title = {Clinical implications of PD ‐ L1 expression in oncogene‐driven NSCLC : Differential responses to targeted agents and immune checkpoint inhibitors},
journal = {International Journal of Cancer},
year = {2026},
doi = {10.1002/ijc.70413}
}
EUVIMED